Compare Novavax Inc (NVAX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while Regeneron Pharmaceuticals Inc trades at $680.5 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 54.2× Novavax Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | REGN | |
|---|---|---|
Market Cap | $1.30B | $70.47B |
Sector | Health | Health |
52-Week High | $11.19 | $812.27 |
52-Week Low | $6.22 | $545.46 |
Enterprise Value | $800.50M | $64.42B |
Dividend Yield | — | 0.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
